chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Myalgia
Clinical narrative: muscle and joint soreness; muscle and joint soreness; This is a spontaneous report from contactable consumer, the patient. A 63-year-old female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA; Lot Number: unknown), via an unspecified route of administration in the left arm on 19Mar2021 at 16:00 (at the age of 63-years-old) as a single dose for COVID-19 immunisation. Medical history included type II diabetes. The patient was allergic to strawberries and bee stings. Concomitant medications included metformin (MANUFACTURER UNKNOWN) and levothyroxine (MANUFACTURER UNKNOWN) for unknown indication. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA; Lot Number: unknown), via an unspecified route of administration in the left arm on 26Feb2021 at 14:00 (at the age of 62-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Mar2021 at 08:00, the patient experienced muscle and joint soreness. The patient took ibuprofen as a treatment for the reported events. The clinical outcome of muscle and joint soreness was resolving at this time of report.   Information about lot/batch number cannot be obtained. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Ear infection, Sinusitis
Clinical narrative: I got the ear and sinus infection; I got the ear and sinus infection; This is a spontaneous report from a contactable consumer. A patient of an unspecified age and gender received BNT162B2 (Pfizer-Biontech COVID-19 vaccine, solution for injection, batch/lot number: unspecified, Expiration date: Not reported), via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. On an unspecified date, got the Covid shot a week ago, the patient got the ear and sinus infection. The outcome of the event was unknown.  Limited information was available over the call.  No follow-up attempts are possible; information about lot/batch number cannot been obtained.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Vaccination site erythema, Vaccination site swelling, Vaccination site warmth
Clinical narrative: Heat surrounding injection site; Swelling surrounding injection site; Redness surrounding injection site; This is spontaneous report from a non-contactable consumer, the patient. A 39-years-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534), via an unspecified route of administration in the left arm on 18Mar2021 (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia, allergy to latex, codeine (MANUFACTURER UNKNOWN) and neomycin (MANUFACTURER UNKNOWN) both since an unknown date. Concomitant medications were not reported. The patient received unspecified vaccines within 4 weeks prior to the COVID vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EL9269), via an unspecified route of administration on 16Feb2021, (at the age of 39-year-old) as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 19Mar2021 at 20:00, the patient experienced swelling, redness and heat surrounding the injection site. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of swelling surrounding injection site, redness surrounding injection site and heat surrounding injection site were not recovered at the time of this report.   No follow-up attempts possible. No further information expected.
Age: 26.0
Sex: M
Vaccine: COVID19
Symptoms: Rash, Vomiting
Clinical narrative: bilateral rash on armpits; Threw-up after 2 hours of vaccine; This is a spontaneous report received from a contactable consumer, the patient. A 26-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; lot number: unknown) in the left arm via an unspecified route on 13Mar2021 at 11:30 as a single dose (at the age of 26-years-old) for COVID-19 immunisation. The patient had no known allergies. Medical history, past drug history and concomitant medications were not reported. The patient did not receive any other vaccination within four weeks prior to the COVID-19 vaccine. The patient did not receive any other medication within two weeks of vaccination. Prior to the vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 13Mar2021 at 02:00, the patient had threw-up 2 hours after vaccine (vomiting) and bilateral rash on armpits. The patient did not receive any treatment for this event. The clinical outcome of the event bilateral rash on armpits and vomiting was recovering at the time of report.   Information about lot number cannot be obtained. No further information is expected.
Age: 48.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Pain, Pyrexia
Clinical narrative: Chills and fever 12 hours after injection.; Chills and fever 12 hours after injection.; Lingering body aches; This is a spontaneous report from a non-contactable consumer, the patient. A 48-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: er2613), via an unspecified route of administration in the left arm on an unspecified date in Mar2021 at 10:30 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. Medical history included diabetes. Concomitant medication included metformin (MANUFACTURER UNKNOWN) for an unknown indication from an unspecified date and unknown if ongoing. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: en6201) via an unspecified route of administration in the left arm on an unspecified date in Feb2021 at 10.30 (at the age of 48-years-old), as a single dose for COVID-19 immunisation. The patient did not have allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unspecified date in Mar2021 at 23:30, the patient experienced chills and fever twelve hours after injection and later it subsided after twelve hours. The patient also had lingering body aches. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive treatment for the reported events. The clinical outcome of the events chills, fever and lingering body aches was recovering at the time of this report.  No follow-up attempts are possible. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Dizziness, Fatigue, Headache, Paraesthesia
Clinical narrative: HEADACHE; Rash (chest and neck); Fatigue; Chills; Dizziness; Tingly skin; This is a spontaneous report received from a contactable consumer, the patient. A 64-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via unspecified route of administration in left arm on 18Mar2021 at 16:30 (at the age of 64 years old) as a single dose for COVID-19 immunisation. Medical history included immune thrombocytopenic purpura (ITP). Concomitant medication was not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6205), via an unspecified route of administration in left arm on 27Feb2021 at 16:45 (at the age of 64 years old) as a single dose for COVID-19 immunisation. The patient had a history of allergy to Bactrim DS (Anaphylaxis) and Amoxicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine.  On 18Mar2021, the patient experienced headache, rash on chest and neck, fatigue, chills, dizziness and tingly skin. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, rash on chest and neck, fatigue, chills, dizziness and tingly skin were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 64.0
Sex: F
Vaccine: COVID19
Symptoms: Rash
Clinical narrative: HEADACHE; Rash (chest and neck); Fatigue; Chills; Dizziness; Tingly skin; This is a spontaneous report received from a contactable consumer, the patient. A 64-year-old, non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: ER8727) via unspecified route of administration in left arm on 18Mar2021 at 16:30 (at the age of 64 years old) as a single dose for COVID-19 immunisation. Medical history included immune thrombocytopenic purpura (ITP). Concomitant medication was not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: EN6205), via an unspecified route of administration in left arm on 27Feb2021 at 16:45 (at the age of 64 years old) as a single dose for COVID-19 immunisation. The patient had a history of allergy to Bactrim DS (Anaphylaxis) and Amoxicillin. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine.  On 18Mar2021, the patient experienced headache, rash on chest and neck, fatigue, chills, dizziness and tingly skin. The patient did not receive any treatment for the reported events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events headache, rash on chest and neck, fatigue, chills, dizziness and tingly skin were recovering at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 39.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Muscle spasms
Clinical narrative: Headache; Calf muscle cramping; This is a spontaneous report from a contactable nurse, the patient. A 39-year-old, non-pregnant female patient received the second dose of BNT162b2 (PFIZER- BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 20Mar2021 at 16:00 (at the age of 39-years-old), as a single dose for COVID-19 immunisation. Medical history included depression and anxiety. The patient was allergic to sulfa and penicillin. Concomitant medications included loryna (YAZ), bupropion hydrochloride (WELLBUTRIN), escitalopram oxalate (LEXAPRO) and loratadine (CLARITIN); all for an unknown indication from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER- BIONTECH COVID-19 mRNA VACCINE, Lot number: UNKNOWN), via an unspecified route of administration in the left arm on 27Feb2021 at 16:00 (at the age of 39-years-old), as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient was not diagnosed with COVID-19 prior to the vaccination. Since the vaccination, the patient had not been tested for COVID-19. On 21Mar2021 at 06:00, the patient experienced headache and calf muscle cramping. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. No therapeutic measures were taken as a result of headache and calf muscle cramping. The clinical outcome of headache and calf muscle cramping was not resolved at the time of report.  No follow-up attempt is possible. No further information is expected.
Age: 81.0
Sex: F
Vaccine: COVID19
Symptoms: Pruritus, Vaccination site erythema, Vaccination site swelling
Clinical narrative: Vaccination site redness; Vaccination site swollen; Itchy; This is a spontaneous report received from a contactable consumer, the patient. An 81-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, lot number: EP7534) at arm on 16Mar2021 at 13:30 (at the age of 81-year-old) as single dose for COVID-19 immunisation. The patient's medical history included cancer, chronic fatigue and allergy (to unknown substances and corn). The patient's concomitant medications included ADDERAL, thyroid medication (unspecified) for unknown indication. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 19Mar2021, about half of upper arm about an inch below where the shot was given turned red and was swollen and itchy and the patient marked the area with pen. On 21Mar2021, the area patient marked with a pen has gotten lighter but the redness has spread outside the marked area and was darker red than the initial redness. The patient did not receive any treatment for events. The clinical outcome of events vaccination site redness, vaccination site swollen and itchy were not resolved. No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Abdominal pain, Discomfort, Fatigue, Neck pain, Pain in extremity
Clinical narrative: Neck pain; Sore discomfort; Runny nose; Abdominal cramps; Sore arm; Fatigue; This is a spontaneous report from a contactable healthcare professional. A 38-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via intramuscular route in the left arm on 19Mar2021 at 10:30 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food, or other products. Prior to vaccination, the patient was diagnosed with COVID-19. The patient did not receive any concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, the patient had not tested positive for COVID-19. On 19Mar2021 at 1100, the patient experienced sore arm, fatigue, neck pain, sore discomfort, runny nose and abdominal cramps. It was reported that adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was reported that no treatment was taken for the events experienced. The clinical outcome of the events sore arm, fatigue, neck pain, sore discomfort, runny nose and abdominal cramps were resolving at the time of this report. No follow-up attempts are possible. No further information is expected.
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Rhinorrhoea
Clinical narrative: Neck pain; Sore discomfort; Runny nose; Abdominal cramps; Sore arm; Fatigue; This is a spontaneous report from a contactable healthcare professional. A 38-year-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via intramuscular route in the left arm on 19Mar2021 at 10:30 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history was not reported. The patient had no known allergies to medications, food, or other products. Prior to vaccination, the patient was diagnosed with COVID-19. The patient did not receive any concomitant medications within 2 weeks of vaccination. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Since the vaccination, the patient had not tested positive for COVID-19. On 19Mar2021 at 1100, the patient experienced sore arm, fatigue, neck pain, sore discomfort, runny nose and abdominal cramps. It was reported that adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. It was reported that no treatment was taken for the events experienced. The clinical outcome of the events sore arm, fatigue, neck pain, sore discomfort, runny nose and abdominal cramps were resolving at the time of this report. No follow-up attempts are possible. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Dizziness
Clinical narrative: very slight and brief light headedness; This is a spontaneous report received from a contactable consumer. A 79years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on the left arm on 20Mar2021(at the age of 79 years-old) at 13:15  as single dose for COVID-19 immunisation. Medical history of the patient included high blood pressure. Concomitant medications were not  reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19.  The patient experienced light headedness on 20Mar2021 at 13:15. The patient reported as very slight and brief light headedness right after administration of vaccine. The patient did not receive treatment for the reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of dizziness was recovered on an unknown date in Mar2021.  Information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Cough, Headache, Lymphadenopathy, Malaise
Clinical narrative: Head ache; Muscle ache; Malaise; Fever; Chills; Swollen lymph nodes; Runny nose; Sore throat; Coughing up greenish/brown phlegm; Sinus congestion; URI; This is a spontaneous report from a contactable consumer. A 45-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration, on 17Mar2021, at 11:00, (at the age of 45 years), on left arm, as a single dose for COVID-19 immunisation. Medical history included Crohns, colitis and allergy to gabapentin, Lyrica and pecans. Concomitant medication was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202) via an unspecified route of administration, on 24Feb2021, at 11:00, on left arm, as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 18Mar2021, at 03:00, the patient experienced head ache, muscle ache, malaise, fever, chills, swollen lymph nodes, runny nose, sinus congestion, sore throat, and cough. These have turned into an upper respiratory tract infection. The patient had sinus phlegm that was green/brown. It had now started to set up in the patients chest and the patient was coughing up greenish/brown phlegm. The treatment received as a result of events included unspecified antibiotics and the events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of head ache, muscle ache, malaise, fever, chills, swollen lymph nodes, runny nose, sinus congestion, sore throat, upper respiratory track infection, and cough were recovering.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Myalgia, Oropharyngeal pain, Pyrexia, Rhinorrhoea, Sinus congestion
Clinical narrative: Head ache; Muscle ache; Malaise; Fever; Chills; Swollen lymph nodes; Runny nose; Sore throat; Coughing up greenish/brown phlegm; Sinus congestion; URI; This is a spontaneous report from a contactable consumer. A 45-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration, on 17Mar2021, at 11:00, (at the age of 45 years), on left arm, as a single dose for COVID-19 immunisation. Medical history included Crohns, colitis and allergy to gabapentin, Lyrica and pecans. Concomitant medication was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202) via an unspecified route of administration, on 24Feb2021, at 11:00, on left arm, as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 18Mar2021, at 03:00, the patient experienced head ache, muscle ache, malaise, fever, chills, swollen lymph nodes, runny nose, sinus congestion, sore throat, and cough. These have turned into an upper respiratory tract infection. The patient had sinus phlegm that was green/brown. It had now started to set up in the patients chest and the patient was coughing up greenish/brown phlegm. The treatment received as a result of events included unspecified antibiotics and the events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of head ache, muscle ache, malaise, fever, chills, swollen lymph nodes, runny nose, sinus congestion, sore throat, upper respiratory track infection, and cough were recovering.   No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: M
Vaccine: COVID19
Symptoms: Upper respiratory tract infection
Clinical narrative: Head ache; Muscle ache; Malaise; Fever; Chills; Swollen lymph nodes; Runny nose; Sore throat; Coughing up greenish/brown phlegm; Sinus congestion; URI; This is a spontaneous report from a contactable consumer. A 45-year-old male patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EP7534) via an unspecified route of administration, on 17Mar2021, at 11:00, (at the age of 45 years), on left arm, as a single dose for COVID-19 immunisation. Medical history included Crohns, colitis and allergy to gabapentin, Lyrica and pecans. Concomitant medication was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202) via an unspecified route of administration, on 24Feb2021, at 11:00, on left arm, as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 18Mar2021, at 03:00, the patient experienced head ache, muscle ache, malaise, fever, chills, swollen lymph nodes, runny nose, sinus congestion, sore throat, and cough. These have turned into an upper respiratory tract infection. The patient had sinus phlegm that was green/brown. It had now started to set up in the patients chest and the patient was coughing up greenish/brown phlegm. The treatment received as a result of events included unspecified antibiotics and the events resulted in doctor or other healthcare professional office/clinic visit. The clinical outcome of head ache, muscle ache, malaise, fever, chills, swollen lymph nodes, runny nose, sinus congestion, sore throat, upper respiratory track infection, and cough were recovering.   No follow-up attempts are needed. No further information is expected.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Chills, Headache, Nausea, Pain
Clinical narrative: fever at 100.5; aching body; Chills; Headache; Nausea; This is a spontaneous report received from a non-contactable consumer, the patient. A 16-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: unknown) via an unspecified route of administration in the left arm on 17Mar2021 at 02:30 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. The patients medical history and concomitant medications were not reported and had no known allergies. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: unknown) via an unspecified route of administration in the left arm on 17Feb2021 02:30, as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Mar2021 at 02:30, the patient experienced fever at 100.5, aching body, chills, headache and nausea. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever at 100.5, aching body, chills, headache and nausea was recovered on an unknown date in 2021.  No follow-up attempts are possible. Information about lot number cannot be obtained.
Age: 16.0
Sex: F
Vaccine: COVID19
Symptoms: Pyrexia
Clinical narrative: fever at 100.5; aching body; Chills; Headache; Nausea; This is a spontaneous report received from a non-contactable consumer, the patient. A 16-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: unknown) via an unspecified route of administration in the left arm on 17Mar2021 at 02:30 (at the age of 16-year-old) as a single dose for COVID-19 immunisation. The patients medical history and concomitant medications were not reported and had no known allergies. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: unknown) via an unspecified route of administration in the left arm on 17Feb2021 02:30, as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 17Mar2021 at 02:30, the patient experienced fever at 100.5, aching body, chills, headache and nausea. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events fever at 100.5, aching body, chills, headache and nausea was recovered on an unknown date in 2021.  No follow-up attempts are possible. Information about lot number cannot be obtained.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Fatigue
Clinical narrative: Tiredness; did not have the usual energy level to do normal activities.; This is a spontaneous report from a non-contactable consumer, the patient. A 57-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the left arm on 18Mar2021 at 13.45, (at the age of 57-years-old) as a single dose for COVID-19 immunisation. The patient had no medical history and did not have allergies to medications, food, or other products. The concomitant medications were not reported. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: unknown) via an unspecified route of administration in the left arm on 24Feb2021 at 13.30, (at the age of 57-years old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient experienced tiredness and did not have the usual energy level to do her normal activities on 19Mar2021 at 10.00. The patient did not receive any treatment for the reported events. The events did not resulted in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events tiredness and did not have the usual energy level to do normal activities was resolved on an unknown date in Mar2021.   No follow up attempts are possible. No further information is expected.
Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Headache, Pain in extremity
Clinical narrative: Pain in arm; Headaches; This is a spontaneous report from a non-contactable consumer. A 56-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: UNKNOWN) via unspecified route of administration in left arm, on 12Mar2021 at 10:00 (at the age of 56 years) as a single dose for COVID-19 immunisation. Medical history included high blood pressure. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. The patient received unspecified medications within 2 weeks of vaccination. On 12Mar2021 at 10:15 hours, the patient experienced pain in arm for about two days, headaches starting about 10 minutes after injection. still having multiple daily headaches eight days later. No therapeutic measures were taken as result of the events. The adverse events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome for the events pain in arm and headache were not recovered at the time of report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Body temperature, Lethargy, Pain, Pyrexia
Clinical narrative: Fever of 99.3-99.8; No energy; Feeling severe aches; This is a spontaneous report received from a contactable consumer, the patient. A 45-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6202) via an unspecified route of administration in right arm on 17Mar2021 at 16:45 (at the age of 45-year-old), as a single dose for COVID-19 immunisation. The patient medical history included uterine cancer in 2010, low thyroid and overweight. Concomitant medications included unspecified medications within two weeks of vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198) via an unspecified route of administration in left arm on 24Feb2021 at 16:30 (at the age of 45-year-old)), as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 18Mar2021 at 09:00, the patient woke up feeling severe aches and no energy. The patient literally did not move for hours and very little as possible and also had a fever of 99.3-99.8 (body temperature with unspecified unit) through the day and night. The patient did not receive any treatment for events. The events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events feeling severe aches, fever and no energy were recovered on 19Mar2021 (next day the patient felt fine again.).   No follow-up attempts are needed. No further information is expected.
Age: 30.0
Sex: M
Vaccine: COVID19
Symptoms: Testicular pain, Testicular swelling
Clinical narrative: Testicles swelled up to about three times their normal size; Extremely sensitive testicles; This is a spontaneous report received from a contactable consumer, the patient. A 30-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6199), via an unspecified route of administration in the left arm on 19Mar2021 at 15:45 (at the age of 30-years-old), as a single dose for COVID-19 immunisation. Medical history included penicillin allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other medications within 2 weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Em9809), via an unspecified route of administration in the left arm on 25Feb2021 at 16:00 (at the age of 30-years-old), as a single dose for COVID-19 immunisation. Since the vaccination, the patient had not been tested positive for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccination. On 20Mar2021 at 01:00, the patient experienced normal side effects, additionally testicles swelled up to about three times their normal size and were extremely sensitive. This persisted to about the 16-hour mark after the patient received the vaccine. The patient did not receive any treatment for the reported events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events testicles swelled up to about three times their normal size and extremely sensitive were recovered on an unspecified date in Mar2021.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Lymphadenopathy, Nausea, Vaccination site discomfort
Clinical narrative: Discomfort at injection site; Lymphadenopathy; Nausea; Headache; Severe fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 61-year-old non-pregnant female patient received unknown dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6207), via an unspecified route of administration in the left arm on 18Mar2021 (at the age of 61-years-old), as a single dose for COVID-19 immunisation. Medical history included ovarian cancer, diabetes, hypertension and adhesives allergy. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient received unspecified medications within 2 weeks of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 18Mar2021 at 16:00, the patient experienced severe fatigue, headache, lymphadenopathy, nausea and discomfort at injection site. The patient did not receive any treatment for the events. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events of severe fatigue, headache, lymphadenopathy, nausea and discomfort at injection site was recovered on an unspecified date in Mar2021.  No follow-up attempts are possible. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Contusion, Pain in extremity
Clinical narrative: Bruised feeling; Left arm sore; This is a spontaneous report received from a contactable consumer, the patient. A 45-years-old non-pregnant female patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on the left arm, on 09Mar2021 at 13:00, as a single dose for COVID-19 immunisation (at the age of 45-years-old). Medical history included high blood pressure (controlled with medication). Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within 4 weeks prior to the COVID-19 vaccine. The patient received unknown medications within 2 weeks of vaccination. It was reported that the patient was allergic to sulfer, bacterium and avelox. On 09Mar2021 at 15:00, the patient experienced pain in arm. It was reported that the patient took Tylenol for the pain. Patient reported that the left arm was sore for 2 days went away, 5 days later on 14Mar2021 the pain came back bruised feeling and very warm to touch. It was day 11 past injection day and it was still sore. The adverse event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of events pain in arm and bruised feeling was not resolved at the time of this report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Breast pain, Breast tenderness
Clinical narrative: Pain in left breast; extreme tenderness in left breast outer and bottom quadrants; This is a spontaneous report received from a contactable other healthcare professional, the patient. A 45 years-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: EN6198) via an unspecified route administration on the left arm on 03Mar2021 at 10:30, (at the age of 45 years) as a single dose, for COVID-19 immunisation. Medical history includes allergic asthma, hypothyroidism and dense breasts. The patient had anaphylactic allergy to salmon and latex allergy. Concomitant medications include SYNTHROID, AVIANE OC (oral contraceptive), probiotic (MANUFACTURER UNKNOWN), W-3 fish oil, B3 (MANUFACTURER UNKNOWN); all started on an unknown date for unknown indication and unknown if ongoing. The patient did not receive any other vaccines within two weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested positive for COVID-19. On 03Mar2021 at 23:00, the patient experienced pain and extreme tenderness in her left breast that started about 12 hours after vaccination; tenderness was in the outer and bottom quadrants. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken for the event which included cold packs. The clinical outcome of the events pain in left breast and extreme tenderness in left breast, outer and bottom quadrants were resolved on an unknown date in Mar2021 (after 2 weeks with use of frequent cold packs). No follow-up attempts are needed. No further information was expected.
Age: 21.0
Sex: F
Vaccine: COVID19
Symptoms: Lymphadenopathy
Clinical narrative: swollen lymph node glands; This is a spontaneous report received from a contactable consumer, the patient. A 21years old non pregnant female patient received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number EN6208) via an unspecified route of administration in left arm on 18Mar2021 at 16:15 as a single dose(at the age of 21years) for COVID-19 immunisation. Medical history was not reported. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not allergic to medications, food or other products. Prior to the vaccination, the patient was diagnosed with COVID-19 on an unknown date. Concomitant drugs include LO LOESTRIN FE from an unknown date for unspecified indication. On 20Mar2021 at 12:00, the patient experienced swollen lymph node glands under vaccination arm. The patient was not treated with any medication for the events. The events did not result in doctor or other healthcare professional office/clinic, emergency room/department or urgent care. The clinical outcome of swollen lymph node glands was not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 69.0
Sex: M
Vaccine: COVID19
Symptoms: Paraesthesia
Clinical narrative: This is a spontaneous report from a contactable pharmacist. A 69-year-old male patient received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE; Lot number: unknown), via intramuscular route of administration in the left arm on 16Mar2021 (at the age of 69-years-old) as a single dose for COVID-19 immunisation. The patient had a history of allergy to penicillin. The concomitant medication was not reported. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient had not diagnosed with COVID-19. Since the vaccination, the patient had not tested positive for COVID-19. On 16Mar2021 the patient experienced tingling under both eyes at rest. The patient did not receive any treatment for reported event. The event didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event tingling under both eyes at rest was not recovered. Information about lot/batch number cannot be obtained. No further information is expected.
Age: 63.0
Sex: F
Vaccine: COVID19
Symptoms: Herpes zoster
Clinical narrative: Shingles on right side of abdomen; This is a spontaneous report received from a contactable nurse, the patient. A 63-year-old non pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: unknown) via an unspecified route of administration in the left arm on 08Jan2021 at 08:00 (at the age of 63-year-old) as a single dose for COVID-19 immunisation. The patient did not have any medical condition. The patient did not have any allergies to medications, food, or other products. Concomitant medications included Vitamin D (MANUFACTURER UNKNOWN) within 2 weeks of vaccination and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot no: unknown) via an unspecified route of administration in the left arm on 18Dec2020 at 07:00 as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 08Mar2021, the patient experienced shingles on right side of abdomen. The patient stated that she was diagnosed with shingles on her right side of abdomen. The rash appeared on 08Mar2021 but there was pain for one week prior to the rash appearing. Patient was healthy and have not had shingles before and she did not have the shingles vaccine. The event resulted in doctor or other healthcare professional office/clinic visit. The patient received antiviral medication (unspecified) for the event shingles. The clinical outcome of the event shingles on right side of abdomen was resolving at the time of the report.   Information about lot/batch number cannot be obtained. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Fatigue, Headache, Hypoaesthesia, Influenza, Nausea
Clinical narrative: body aches; fatigue; sinus pressure; headache; nausea; general flu symptoms; tingle; numb; This is a spontaneous report from a contactable other health care professional, the patient. A 23-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261), via an unspecified route of administration on 15Feb2021 (23-year-old at the time of vaccination) at 1500 as a single dose for COVID-19 immunisation. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9262) via an unspecified route of administration on 24Jan2021 at 1100 as a single dose for COVID-19 immunisation.   The patient had no medical history. Prior to the COVID vaccine within the four weeks the patient did not receive any other vaccines. Prior to the vaccine the patient was not diagnosed with COVID-19.  Concomitant medications included ibuprofen(MANUFACTURER UNKNOWN). Patient had not tested positive for COVID-19 since having the vaccine. On 15Feb2021, the patient reported that about three hours after receiving the vaccine, the left side of her face (the cheek beginning at her eyebrow and going down to her jaw) began to noticeably hurt, but mildly enough that she could continue normal activities. Then, within a half hour it began to tingle and soon after went numb for about two or three hours. It returned to normal that evening. On 16Feb2021, the patient experienced body aches, fatigue, sinus pressure, headache, nausea and Just typical general flu symptoms. No therapeutic measures were taken for the reported events. The clinical outcome of the events tingling and numbness were recovered on 15Feb2021; while that of body aches, fatigue, sinus pressure, headache, nausea and general flu symptoms were unknown at the time of this report.   No follow up attempts are needed. No further information is expected.
Age: 23.0
Sex: F
Vaccine: COVID19
Symptoms: Pain, Paraesthesia, Paranasal sinus discomfort
Clinical narrative: body aches; fatigue; sinus pressure; headache; nausea; general flu symptoms; tingle; numb; This is a spontaneous report from a contactable other health care professional, the patient. A 23-year-old non-pregnant female patient received second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9261), via an unspecified route of administration on 15Feb2021 (23-year-old at the time of vaccination) at 1500 as a single dose for COVID-19 immunisation. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL9262) via an unspecified route of administration on 24Jan2021 at 1100 as a single dose for COVID-19 immunisation.   The patient had no medical history. Prior to the COVID vaccine within the four weeks the patient did not receive any other vaccines. Prior to the vaccine the patient was not diagnosed with COVID-19.  Concomitant medications included ibuprofen(MANUFACTURER UNKNOWN). Patient had not tested positive for COVID-19 since having the vaccine. On 15Feb2021, the patient reported that about three hours after receiving the vaccine, the left side of her face (the cheek beginning at her eyebrow and going down to her jaw) began to noticeably hurt, but mildly enough that she could continue normal activities. Then, within a half hour it began to tingle and soon after went numb for about two or three hours. It returned to normal that evening. On 16Feb2021, the patient experienced body aches, fatigue, sinus pressure, headache, nausea and Just typical general flu symptoms. No therapeutic measures were taken for the reported events. The clinical outcome of the events tingling and numbness were recovered on 15Feb2021; while that of body aches, fatigue, sinus pressure, headache, nausea and general flu symptoms were unknown at the time of this report.   No follow up attempts are needed. No further information is expected.